Profile data is unavailable for this security.
About the company
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
- Revenue in USD (TTM)29.40m
- Net income in USD-352.62m
- Incorporated2007
- Employees383.00
- LocationAgios Pharmaceuticals Inc88 Sidney StreetCAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 649-8600
- Fax+1 (302) 655-5049
- Websitehttps://www.agios.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avadel Pharmaceuticals PLC (ADR) | 27.96m | -160.28m | 1.81bn | 154.00 | -- | 19.28 | -- | 64.69 | -2.04 | -2.04 | 0.3491 | 0.9768 | 0.188 | -- | 4.52 | 181,577.90 | -107.75 | -40.21 | -156.49 | -47.99 | 96.97 | -- | -573.17 | -374.75 | 3.36 | -13.94 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Fusion Pharmaceuticals Inc | 2.07m | -94.90m | 1.82bn | 113.00 | -- | 7.68 | -- | 881.29 | -1.47 | -1.47 | 0.0315 | 2.79 | 0.0082 | -- | 60.82 | 18,300.88 | -37.59 | -35.45 | -40.07 | -38.55 | -- | -- | -4,588.83 | -7,206.24 | -- | -- | 0.1352 | -- | 41.55 | -- | -8.32 | -- | 28.21 | -- |
| Edgewise Therapeutics Inc | 0.00 | -100.16m | 1.82bn | 88.00 | -- | 4.31 | -- | -- | -1.57 | -1.57 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -28.33 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -89.62m | 1.83bn | 93.00 | -- | 4.03 | -- | -- | -2.51 | -2.51 | 0.00 | 9.76 | 0.00 | -- | -- | 0.00 | -30.91 | -- | -33.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Syndax Pharmaceuticals Inc | 0.00 | -209.36m | 1.87bn | 112.00 | -- | 3.38 | -- | -- | -2.96 | -2.96 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -37.72 | -27.90 | -40.93 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| Beam Therapeutics Inc | 377.71m | -132.53m | 1.90bn | 436.00 | -- | 1.92 | -- | 5.04 | -1.87 | -1.87 | 4.90 | 12.02 | 0.2697 | -- | -- | 866,305.10 | -9.46 | -24.54 | -11.17 | -29.26 | -- | -- | -35.09 | -211.96 | -- | -- | 0.0005 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Ginkgo Bioworks Holdings Inc | 251.46m | -892.87m | 1.94bn | 1.22k | -- | 1.74 | -- | 7.72 | -0.459 | -0.459 | 0.1293 | 0.5482 | 0.1196 | 24.49 | 5.01 | 206,449.10 | -42.47 | -- | -46.17 | -- | 78.52 | -- | -355.08 | -- | 6.11 | -1,703.31 | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| Agios Pharmaceuticals Inc | 29.40m | -352.62m | 1.96bn | 383.00 | -- | 2.63 | -- | 66.69 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Ardelyx Inc | 124.46m | -66.07m | 2.03bn | 267.00 | -- | 12.15 | -- | 16.30 | -0.3038 | -0.3038 | 0.5643 | 0.7176 | 0.5104 | 2.26 | 8.36 | 466,127.30 | -27.10 | -46.14 | -35.55 | -57.32 | 85.70 | 88.15 | -53.08 | -240.87 | 4.64 | -12.70 | 0.23 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Amphastar Pharmaceuticals Inc | 644.40m | 137.55m | 2.07bn | 1.76k | 16.41 | 3.19 | 11.69 | 3.22 | 2.59 | 2.59 | 12.16 | 13.30 | 0.5716 | 2.78 | 6.33 | 365,925.60 | 12.38 | 9.42 | 14.42 | 11.56 | 54.91 | 47.83 | 21.65 | 15.23 | 1.70 | 10.68 | 0.4799 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Amneal Pharmaceuticals Inc | 2.39bn | -83.99m | 2.09bn | 7.70k | -- | 156.75 | 11.54 | 0.8714 | -0.3116 | -0.3116 | 13.46 | 0.0431 | 0.6583 | 2.83 | 3.53 | 310,858.10 | -1.34 | -4.80 | -1.70 | -5.93 | 34.28 | 34.76 | -2.04 | -9.00 | 0.9408 | 1.14 | 0.9778 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Deciphera Pharmaceuticals Inc | 163.36m | -194.94m | 2.09bn | 355.00 | -- | 5.82 | -- | 12.78 | -2.29 | -2.29 | 1.92 | 4.36 | 0.3522 | 0.1787 | 6.01 | 460,157.80 | -42.03 | -44.54 | -52.63 | -52.24 | 97.72 | -- | -119.34 | -245.88 | 3.59 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| Recursion Pharmaceuticals Inc | 44.58m | -328.07m | 2.10bn | 500.00 | -- | 4.46 | -- | 47.10 | -1.57 | -1.57 | 0.2145 | 1.98 | 0.0658 | -- | 15.25 | 89,150.00 | -48.42 | -- | -56.49 | -- | 4.46 | -- | -735.99 | -- | -- | -- | 0.0025 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Agios Pharmaceuticals Inc's reporting currency: US Dollar USD
58.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Jan 2024 | 5.60m | 9.97% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 4.31m | 7.68% |
| Farallon Capital Management LLCas of 31 Dec 2023 | 4.17m | 7.42% |
| Bellevue Asset Management AGas of 31 Dec 2023 | 4.01m | 7.14% |
| Armistice Capital LLCas of 31 Dec 2023 | 3.52m | 6.27% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.63m | 4.67% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 2.60m | 4.62% |
| Rock Springs Capital Management LPas of 31 Dec 2023 | 2.15m | 3.83% |
| Macquarie Investment Management Business Trustas of 31 Dec 2023 | 2.02m | 3.59% |
| First Trust Advisors LPas of 31 Dec 2023 | 1.82m | 3.24% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
